Humacyte, Inc.

Humacyte, Inc. (Nasdaq: HUMA) is a clinical-stage biotechnology company that entered the public markets through a business combination with Alpha Healthcare Acquisition Corp. (AHAC), a healthcare-focused special purpose acquisition company sponsored by Alpha Healthcare Capital, LLC that completed its IPO in 2020. The February 2021 Form 8-K filing reflects a disclosure event during the period surrounding the announced merger, which brought Humacyte's bioengineered human acellular vessel technology into the public markets. Operating in the life sciences and regenerative medicine sector, the company trades under the HUMA ticker on Nasdaq following the completed combination. For full deal data, sponsor details, and filing history on HUMA, sign up for SpacDesk.